Participants 106 133 6
patients with liver failure
Participants 290 317 5
subjects with liver failure
Participants 517 601 9
146 patients with liver failure and prothrombin time activity percentage (PTA) â‰¤ 4
Participants 639 728 9
: 92 MARS treatment sessions in the heparin-free group and 82 in the low-dose heparin gro
